Statistical Models for Censored Point Processes with Cure Rates

Similar documents
Joint Modelling of Event Counts and Survival Times: Example Using Data from the MESS Trial

Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial

Treatment outcome after failure of a first antiepileptic drug

The Statistical Analysis of Failure Time Data

p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida

Laura Bonnett, Catrin Tudur Smith, David Smith, Paula Williamson, David Chadwick, Anthony G Marson

ICD-9 to ICD-10 Conversion of Epilepsy

Statistical Tolerance Regions: Theory, Applications and Computation

When to start, which drugs and when to stop

Biostatistics II

Case Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company

University of Warwick institutional repository: A Thesis Submitted for the Degree of PhD at the University of Warwick

Supplementary appendix

Poisson regression. Dae-Jin Lee Basque Center for Applied Mathematics.

Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival

Introduction to Survival Analysis Procedures (Chapter)

Empirical assessment of univariate and bivariate meta-analyses for comparing the accuracy of diagnostic tests

AP Statistics. Semester One Review Part 1 Chapters 1-5

Methods for adjusting survival estimates in the presence of treatment crossover a simulation study

cloglog link function to transform the (population) hazard probability into a continuous

Part [1.0] Introduction to Development and Evaluation of Dynamic Predictions

~.~i. PERFORMING ORGANIZAT in REPORT NUMBER MADISON WI AESSRTR* O

Staging of Seizures According to Current Classification Systems December 10, 2013

Understandable Statistics

Epilepsy DOJ Lecture Masud Seyal, M.D., Ph.D. Department of Neurology University of California, Davis

Motivation Empirical models Data and methodology Results Discussion. University of York. University of York

DEFINITION AND CLASSIFICATION OF EPILEPSY

Treatment effect estimates adjusted for small-study effects via a limit meta-analysis

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study

A Comparison of Shape and Scale Estimators of the Two-Parameter Weibull Distribution

A Predictive Chronological Model of Multiple Clinical Observations T R A V I S G O O D W I N A N D S A N D A M. H A R A B A G I U

Application of EM Algorithm to Mixture Cure Model for Grouped Relative Survival Data

Data Analysis Using Regression and Multilevel/Hierarchical Models

Advanced IPD meta-analysis methods for observational studies

Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531

L J Bonnett, 1 G A Powell, 2 C Tudur Smith, 1 AG Marson 2. Research. Open Access

Estimating and Modelling the Proportion Cured of Disease in Population Based Cancer Studies

June 30 (Fri), Teaching Session 1. New definition & epilepsy classification. Chairs Won-Joo Kim Ran Lee

Meier Hsu, Ann Zauber, Mithat Gönen, Monica Bertagnolli. Memorial-Sloan Kettering Cancer Center. May 18, 2011

Quantifying cancer patient survival; extensions and applications of cure models and life expectancy estimation

LMMG New Medicine Recommendation

Unit 1 Exploring and Understanding Data

Issues for analyzing competing-risks data with missing or misclassification in causes. Dr. Ronny Westerman

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method

Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ

Lecture Outline. Biost 517 Applied Biostatistics I. Purpose of Descriptive Statistics. Purpose of Descriptive Statistics

SUPPLEMENTARY MATERIAL. Impact of Vaccination on 14 High-Risk HPV type infections: A Mathematical Modelling Approach

Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?

Received: 14 April 2016, Accepted: 28 October 2016 Published online 1 December 2016 in Wiley Online Library

Prediction and Inference under Competing Risks in High Dimension - An EHR Demonstration Project for Prostate Cancer

Technology appraisal guidance Published: 27 July 2016 nice.org.uk/guidance/ta399

Overdiagnosis in. Outline

List of Figures. List of Tables. Preface to the Second Edition. Preface to the First Edition

Improving trial methodology: Examples from epilepsy. Tony Marson University of Liverpool

What do we know about prognosis and natural course of epilepsies?

PRACTICAL STATISTICS FOR MEDICAL RESEARCH

Pharmaceutical Statistics Journal Club 15 th October Missing data sensitivity analysis for recurrent event data using controlled imputation

Modeling unobserved heterogeneity in Stata

Benchmark Dose Modeling Cancer Models. Allen Davis, MSPH Jeff Gift, Ph.D. Jay Zhao, Ph.D. National Center for Environmental Assessment, U.S.

Epilepsy. Epilepsy can be defined as:

Epilepsy Specialist Symposium Treatment Algorithms in the Diagnosis and Treatment of Epilepsy

Analysis Strategies for Clinical Trials with Treatment Non-Adherence Bohdana Ratitch, PhD

Estimating Adjusted Prevalence Ratio in Clustered Cross-Sectional Epidemiological Data

Keywords: treatment; epilepsy; population based cohort Institute of Neurology, University College London, London WC1N 3BG, UK

Survival analysis beyond the Cox-model

QUASI- BAYESIAN ESTIMATION FOR INVERSE WEIBULL DISTRIBUTION

Paediatric Epilepsy Update N o r e e n Te a h a n canp C o l e t t e H u r l e y C N S E p i l e p s y

bivariate analysis: The statistical analysis of the relationship between two variables.

Statistical Analysis Plan: Post-hoc analysis of the CALORIES trial

Type of intervention Primary prevention; secondary prevention. Economic study type Cost-effectiveness analysis and cost utility analysis.

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd

Bayesian hierarchical modelling

Computer Age Statistical Inference. Algorithms, Evidence, and Data Science. BRADLEY EFRON Stanford University, California

Applied Medical. Statistics Using SAS. Geoff Der. Brian S. Everitt. CRC Press. Taylor Si Francis Croup. Taylor & Francis Croup, an informa business

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380

Analysis of left-censored multiplex immunoassay data: A unified approach

STATISTICAL APPENDIX

Keywords: Clustered processes; Jump probabilities; Mover stayer model; Multistate model; Psoriatic arthritis; Sojourn times

Analysis of Vaccine Effects on Post-Infection Endpoints Biostat 578A Lecture 3

Statistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks

NICE Single Technology Appraisal of cetuximab for the treatment of recurrent and /or metastatic squamous cell carcinoma of the head and neck

A Comparison of Methods for Determining HIV Viral Set Point

Epilepsy Syndromes: Where does Dravet Syndrome fit in?

Classification of Seizures. Generalized Epilepsies. Classification of Seizures. Classification of Seizures. Bassel F. Shneker

Estimating Testicular Cancer specific Mortality by Using the Surveillance Epidemiology and End Results Registry

EPI 200C Final, June 4 th, 2009 This exam includes 24 questions.

Seizure remission in adults with long-standing intractable epilepsy: An extended follow-up

Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.

Lecture 21. RNA-seq: Advanced analysis

Fundamental Clinical Trial Design

BLISTER STATISTICAL ANALYSIS PLAN Version 1.0

Analyzing diastolic and systolic blood pressure individually or jointly?

Investigation of relative survival from colorectal cancer between NHS organisations

TESTING THE PERFORMANCE OF THE POWER LAW PROCESS MODEL CONSIDERING THE USE OF REGRESSION ESTIMATION APPROACH

TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL. Beth A.

INTERVAL trial Statistical analysis plan for principal paper

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

Some alternatives for Inhomogeneous Poisson Point Processes for presence only data

How many Cases Are Missed When Screening Human Populations for Disease?

Transcription:

Statistical Models for Censored Point Processes with Cure Rates Jennifer Rogers MSD Seminar 2 November 2011

Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Accelerated Failure Time Models Joint Model Joint Modelling of Event Counts and Survival Times Results Extensions to the Simple Joint Model Removal of the Post-Randomisation IID Assumption Allowing for Cure Rates Full Joint Model Model Checking and Further Extensions Model Checking Further Extensions

Background and MESS Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Accelerated Failure Time Models Joint Model Joint Modelling of Event Counts and Survival Times Results Extensions to the Simple Joint Model Removal of the Post-Randomisation IID Assumption Allowing for Cure Rates Full Joint Model Model Checking and Further Extensions Model Checking Further Extensions

Background and MESS Epilepsy Epilepsy Defined as the occurrence of recurrent, unprovoked seizures. ILAE classification scheme divides seizures into partial, generalised or unclassified seizures. Partial - part of the brain; simple or complex; motor, sensory, occipital, frontal lobe and temporal lobe. Can sometimes occur with secondary generalisation Generalised - all of the brain; tonic-clonic (grand mal), absence (petit mal), myoclonic and atonic

Background and MESS MESS Early Epilepsy and Single Seizures On average 50% of people do not experience a recurrence following a first seizure Around 20 30% of people will never achieve long-term remission Antiepileptic drugs (AEDs) come with unpleasant side effects In early epilepsy are AEDs necessary?

Background and MESS MESS The MESS Trial MRC Multicentre Trial for Early Epilepsy and Single Seizures Comparison of policies: immediate vs deferred treatment Randomised 1443 patients Eligibility criteria: Outcomes of interest - time to first seizure, time to second seizure (Marson et al. 2005)

Background and MESS MESS The MESS Trial MRC Multicentre Trial for Early Epilepsy and Single Seizures Comparison of policies: immediate vs deferred treatment Randomised 1443 patients Eligibility criteria: 1. Aged at least one month Outcomes of interest - time to first seizure, time to second seizure (Marson et al. 2005)

Background and MESS MESS The MESS Trial MRC Multicentre Trial for Early Epilepsy and Single Seizures Comparison of policies: immediate vs deferred treatment Randomised 1443 patients Eligibility criteria: 2. Had experienced at least one epileptic seizure Outcomes of interest - time to first seizure, time to second seizure (Marson et al. 2005)

Background and MESS MESS The MESS Trial MRC Multicentre Trial for Early Epilepsy and Single Seizures Comparison of policies: immediate vs deferred treatment Randomised 1443 patients Eligibility criteria: 3. Uncertainty about whether to proceed with treatment Outcomes of interest - time to first seizure, time to second seizure (Marson et al. 2005)

Exploratory Analysis Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Accelerated Failure Time Models Joint Model Joint Modelling of Event Counts and Survival Times Results Extensions to the Simple Joint Model Removal of the Post-Randomisation IID Assumption Allowing for Cure Rates Full Joint Model Model Checking and Further Extensions Model Checking Further Extensions

Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Seizure Type Pre-Randomisation Seizure Type Immediate Deferred Tonic-Clonic 375 406 Partial with 2 Tonic-Clonic 239 215 Partial 51 52 Generalised 21 19 Other 17 13

Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Kaplan-Meier Curves by Treatment Time to First Seizure Time from First to Second Seizure Survival 0.0 0.2 0.4 0.6 0.8 1.0 Immediate Deferred Survival 0.0 0.2 0.4 0.6 0.8 1.0 Immediate Deferred 0 2 4 6 8 0 2 4 6 8 Time in years Time in years

Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Cumulative Distribution Function Empirical Cumulative Distribution Function F 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 (time to first seizure)/(total time to second seizure)

Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Kaplan-Meier Curves by Seizure Type Time to First Seizure Time from First to Second Seizure Survival 0.0 0.2 0.4 0.6 0.8 1.0 Tonic Clonic only Tonic Clonic with Partial Generalised Partial Minor Other Seizures Survival 0.0 0.2 0.4 0.6 0.8 1.0 Tonic Clonic only Tonic Clonic with Partial Generalised Partial Minor Other Seizures 0 2 4 6 8 0 2 4 6 8 Time in years Time in years

Exploratory Analysis Accelerated Failure Time Models Accelerated Failure Time Assumption P-H assumption, for individual i h i (t) = e β z i h 0 (t) (1) Epilepsy data well modelled by distributions that are AFT S i (t) = S 0 (t/e β z i ) (2) (1) e β z i reflects impact of treatment on baseline hazard (2) e β z i reflects impact of treatment on baseline time scale

Exploratory Analysis Accelerated Failure Time Models Testing the AFT Assumption z = 0/1 - allocated to deferred/immediate treatment We define t (a) 0, t(a) 1, for 0 < a < 1, by: a = S 0 (t (a) 0 ) a = S 1(t (a) 1 ) S 1 (t (a) 1 ) = S 0(t (a) 0 ) Then by (2), t (a) 1 = t (a) 0 eβ Percentile-percentile plot to test AFT assumption

Exploratory Analysis Accelerated Failure Time Models Percentile-percentile plots P P plot Time to First Seizure P P plot Time from First to Second Seizure Immediate 0 500 1000 1500 2000 Immediate 0 100 200 300 400 500 0 200 400 600 800 0 100 200 300 400 Deferred Deferred Weibull, Exponential, Log-logistic, Lognormal, Gamma,....

Joint Model Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Accelerated Failure Time Models Joint Model Joint Modelling of Event Counts and Survival Times Results Extensions to the Simple Joint Model Removal of the Post-Randomisation IID Assumption Allowing for Cure Rates Full Joint Model Model Checking and Further Extensions Model Checking Further Extensions

Joint Model Joint Modelling of Event Counts and Survival Times The Data Data arrives in two parts: 1. Pre-randomisation event count, X i - the number of seizures in a given period of time prior to entry to the trial 2. Post-randomisation survival times, (Y 1i, Y 2i ) - times to first and second seizure following randomisation to a treatment policy

Joint Model Joint Modelling of Event Counts and Survival Times Standard Approaches Treatment effects in recurrent events - Cook and Lawless (2007) - rates and mean functions, mixed Poisson model Use of baseline count data - Cook and Lawless (2007) - mixed Poisson processes If datasets exhibit cure rates, focus needs to be on gap times If I have a seizure, am I likely to have another one, and if so, when?

Joint Model Joint Modelling of Event Counts and Survival Times Joint Model The joint model is specified by the following equations: f X ν (x i ν i ; λ i, u i ) = (λ iu i ν i ) x i exp( λ i u i ν i ) x i! f Yj ν(y ji ν i ; λ i, ψ i ) = λ i ψ i ν i exp( λ i ψ i ν i y ji ), j = 1, 2 g ν (ν i ; α) = αα ν α 1 i exp( αν i ) Γ(α) λ i = exp(β 1 z 1i), ψ i = exp(β 2 z 2i), α determines degree of heterogeneity (Cowling et al. 2006)

Joint Model Joint Modelling of Event Counts and Survival Times Graphical Representation β 1 Z 1i α β 2 Z 2i λ i ν i ψ i u i X i Y 1i δ 1i Y 2i δ 2i

Joint Model Joint Modelling of Event Counts and Survival Times Unconditional Distributions Unconditional distribution of X i is Negative Binomial Unconditional joint survivor function of the Y ji, j = 1, 2 is bivariate Lomax f Y1,Y 2 (y 1i, y 2i ; λ i, ψ i, α) = α + 1 { α (λ iψ i ) 2 1 + λ iψ i (y 1i + y 2i ) α { S Y1,Y 2 (y 1i, y 2i ; λ i, ψ i, α) = 1 + λ } α iψ i (y 1i + y 2i ) α Unconditional marginals are univariate Lomax } (α+2)

Joint Model Joint Modelling of Event Counts and Survival Times Log-Logistic and Lomax distributions Log-logistic (shape=a, scale=b) F Y (y i ) = 1 {1 + (y i /b) a } 1 (3) Lomax (shape=a, scale=b) F Y (y i ) = 1 {1 + (y i /b)} a (4) When a = 1, (3) and (4) are equivalent

Joint Model Joint Modelling of Event Counts and Survival Times Log-Logistic Distribution Survivor function S(y) = 1 1 + (y/b) a Consider the following transformation: { } S(y) ln = a ln(y) + a ln(b) 1 S(y) Linear in ln(y)

Joint Model Joint Modelling of Event Counts and Survival Times Justifying the Log-Logistic Distribution Time to First Seizure Time from First to Second Seizure log(survival/(1 Survival)) 0 1 2 3 4 log(survival/(1 Survival)) 1 0 1 2 3 0 2 4 6 8 log(time) 0 2 4 6 8 log(time)

Joint Model Joint Modelling of Event Counts and Survival Times Log-Likelihood Three different scenarios: 1. Y 1i and Y 2i both observed, 2. Y 1i is observed, but Y 2i is censored, and 3. Y 1i is censored Straightforward to derive log-likelihood and derivatives allowing inference using a numerical method such as Newton-Raphson

Joint Model Results Pre-Randomisation Seizure Rates Seizure Type λi (95% C.I.) Expected yearly rate Tonic-Clonic 0.005 (0.005,0.006) 2 2 Tonic-Clonic 0.008 (0.007,0.009) 3 Partial 0.016 (0.013,0.019) 6

Joint Model Results Change in Seizure Rates, Post-Randomisation Seizure Type ψi (95% C.I.) Abnormal EEG Immediate Deferred Tonic-Clonic 0.122 (0.10,0.15) 0.188 (0.15,0.23) 2 Tonic-Clonic 0.127 (0.10,0.16) 0.282 (0.22,0.36) Partial 0.078 (0.05,0.12) 0.074 (0.05,0.11) Normal EEG Immediate Deferred Tonic-Clonic 0.127 (0.10,0.15) 0.134 (0.11,0.16) 2 Tonic-Clonic 0.089 (0.07,0.11) 0.135 (0.11,0.17) Partial 0.195 (0.12,0.32) 0.127 (0.08,0.21)

Extensions to the Simple Joint Model Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Accelerated Failure Time Models Joint Model Joint Modelling of Event Counts and Survival Times Results Extensions to the Simple Joint Model Removal of the Post-Randomisation IID Assumption Allowing for Cure Rates Full Joint Model Model Checking and Further Extensions Model Checking Further Extensions

Extensions to the Simple Joint Model Recall... Risk of future seizures increases with the number of previous seizures Clustering and different treatment effects Time-varying seizure rate On average 50% of people do not experience a recurrence after a single seizure Large reductions in seizure rates Cure rate models

Extensions to the Simple Joint Model Removal of the Post-Randomisation IID Assumption Removal of the Post-Randomisation IID Assumption Evidence to suggest that ψ i may change through time f X ν (x i ν i ; λ i, u i ) = (λ iu i ν i ) x i exp( λ i u i ν i ) x i! f Y1 ν(y 1i ν i ; λ i, ψ 1i ) = λ i ψ 1i ν i exp( λ i ψ 1i ν i y 1i ) f Y2 ν(y 2i ν i ; λ i, ψ 1i, ψ 2i ) = λ i ψ 1i ψ 2i ν i exp( λ i ψ 1i ψ 2i ν i y 2i ) g ν (ν i ; α) = αα ν α 1 i exp( αν i ) Γ(α) λ i = exp(β 1 z 1i), ψ 1i = exp(β 2 z 2i) and ψ 2i = exp(β 3 z 3i)

Extensions to the Simple Joint Model Allowing for Cure Rates Kaplan-Meier Curves Time to First Seizure Time from First to Second Seizure 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 0 2 4 6 8 0 2 4 6 8

Extensions to the Simple Joint Model Allowing for Cure Rates Inclusion of a Cure Fraction Large proportion of individuals immune from future seizures f X ν (x i ν i ; λ i, u i ) = (λ iu i ν i ) x i exp( λ i u i ν i ) x i! f Yj ν(y ji ν i ; λ i, ψ i, p ji ) = p ji λ i ψ i ν i exp( λ i ψ i ν i y ji ) S Yj ν(y ji ν i ; λ i, ψ i, p ji ) = 1 p ji + p ji exp( λ i ψ i ν i y ji ) g ν (ν i ; α) = αα ν α 1 i exp( αν i ) Γ(α) λ i = exp(β 1 z 1i), ψ i = exp(β 2 z 2i) and p ji = exp(κ j w ji ) 1+exp(κ j w ji )

Extensions to the Simple Joint Model Full Joint Model Cure Rate Seizure Type 1 p 1i (95% C.I.) Abnormal EEG Immediate Deferred Tonic-Clonic 0.518 (0.45,0.59) 0.360 (0.20,0.43) 2 Tonic-Clonic 0.389 (0.31,0.48) 0.250 (0.19,0.33) Partial 0.487 (0.36,0.62) 0.332 (0.22,0.46) Normal EEG Immediate Deferred Tonic-Clonic 0.528 (0.47,0.59) 0.511 (0.45,0.57) 2 Tonic-Clonic 0.584 (0.51,0.65) 0.568 (0.50,0.64) Partial 0.345 (0.20,0.52) 0.330 (0.19,0.50) 1 p 2i = 0.26 for all i

Extensions to the Simple Joint Model Full Joint Model Change in Seizure Rates, Following Randomisation Seizure Type ψ1i (95% C.I.) first seizure Abnormal EEG Immediate Deferred Tonic-Clonic 0.347 (0.26,0.47) 0.738 (0.57,0.95) 2 Tonic-Clonic 0.326 (0.24,0.44) 0.786 (0.58,1.06) Partial 0.522 (0.31,0.88) 0.695 (0.41,1.18) Normal EEG Immediate Deferred Tonic-Clonic 0.582 (0.45,0.75) 0.683 (0.53,0.87) 2 Tonic-Clonic 0.467 (0.34,0.65) 0.622 (0.46,0.84) Partial 0.522 (0.27,1.00) 0.384 (0.20,0.73)

Extensions to the Simple Joint Model Full Joint Model Change in Seizure Rates, Following First Seizure Seizure Type ψ2i (95% C.I.) second seizure Abnormal EEG Immediate Deferred Tonic-Clonic 3.806 (2.43,5.97) 1.554 (1.00,2.41) 2 Tonic-Clonic 1.835 (1.17,2.88) 0.870 (0.56,1.36) Partial 2.754 (1.17,6.49) 2.047 (0.98,4.26) Normal EEG Immediate Deferred Tonic-Clonic 1.688 (1.13,2.51) 1.373 (0.93,2.02) 2 Tonic-Clonic 2.727 (1.69,4.41) 2.577 (1.67,3.97) Partial 3.138 (1.28,7.70) 4.649 (1.63,13.27)

Model Checking and Further Extensions Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier Curves Accelerated Failure Time Models Joint Model Joint Modelling of Event Counts and Survival Times Results Extensions to the Simple Joint Model Removal of the Post-Randomisation IID Assumption Allowing for Cure Rates Full Joint Model Model Checking and Further Extensions Model Checking Further Extensions

Model Checking and Further Extensions Model Checking Model Comparisons Joint Model compared with Log-logistic cure rate model Kaplan-Meier estimates and fitted estimates Both models seem to fit data well Cowling et al. (2006) carried out a power analysis Estimates of treatment effects more precise than survival models

Model Checking and Further Extensions Model Checking Comparison with Kaplan-Meier Curves I Time to First Seizure Time from First to Second Seizure Survival 0.0 0.2 0.4 0.6 0.8 1.0 Log logistic with Cure Rate Full Joint Model Survival 0.0 0.2 0.4 0.6 0.8 1.0 Log logistic with Cure Rate Full Joint Model 0 2 4 6 8 0 2 4 6 8 Time in years Time in years

Model Checking and Further Extensions Model Checking Comparison with Kaplan-Meier Curves II Time to First Seizure Time from First to Second Seizure Survival 0.0 0.2 0.4 0.6 0.8 1.0 Log logistic with Cure Rate Full Joint Model Survival 0.0 0.2 0.4 0.6 0.8 1.0 Log logistic with Cure Rate Full Joint Model 0 2 4 6 8 0 2 4 6 8 Time in years Time in years

Model Checking and Further Extensions Further Extensions Extensions not Considered Zero-truncated, one-inflated Poisson Distribution Different AEDs Further post-randomisation survival times Analysis of long-term prognosis

Model Checking and Further Extensions Further Extensions Zero-Truncated, One-Inflated Poisson I Barplot of Number of Seizures Pre randomisation Frequency 0 200 400 600 800 1 2 3 4 5 6 7 8 9 10 11 12 15 Number of Seizures

Model Checking and Further Extensions Further Extensions Zero-Truncated, One-Inflated Poisson II Zero-truncated Poisson(λ i u i ν i ) distribution ZTP(x i ; λ i, u i, ν i ) = (λ iu i ν i ) x i exp( λ i u i ν i ) x i!(1 exp( λ i u i ν i )) = (λ i u i ν i ) xi x i!(exp(λ i u i ν i ) 1). One-inflated, zero-truncated Poisson distribution assumes that f X (x i ; λ i, u i, ν i, π) = πi [xi =1] + (1 π)ztp(x i ; λ i u i ν i ) I [xi =1] is the indicator function taking the value 1 when x i = 1 and zero otherwise

Model Checking and Further Extensions Further Extensions Different AEDs I Two randomisation forms used during the trial Second randomisation strategy allows comparisons between specific drugs

Model Checking and Further Extensions Further Extensions Different AEDs I Two randomisation forms used during the trial 1. Randomisation Drug (614 participants) Second randomisation strategy allows comparisons between specific drugs

Model Checking and Further Extensions Further Extensions Different AEDs I Two randomisation forms used during the trial 1. Randomisation Drug (614 participants) 2. Drug Randomisation (811 participants) Second randomisation strategy allows comparisons between specific drugs

Model Checking and Further Extensions Further Extensions Different AEDs II Antiepileptic drug strongly dependent on a number of baseline covariates, such as: age type of epilepsy nature of the seizures Regress missing items on those influential baseline covariates we have observed Multiple imputation

Summary Summary New modelling strategy for event counts and two survival times Mathematically and computationally straightforward to implement Extensions to simple joint model considered Comparisons made with standard survival techniques Estimates of treatment effect more precise under joint model

Appendix For Further Reading Cook, R. J. and J. F. Lawless (2007). The Statistical Analysis of Recurrent Events. Statistics for Biology and Health. Springer. Cowling, B. J., J. L. Hutton, and J. E. H. Shaw (2006). Joint modelling of event counts and survival times. J. R. Statist. Soc. C 55(1), 31 39. Marson, A., A. Jacoby, A. Johnson, L. Kim, C. Gamble, and D. Chadwick (2005). Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised control trial. The Lancet 365, 2007 2013.